Schroeder Verena, Chatterjee Tushar, Mehta Haresh, Windecker Stephan, Pham Trinh, Devantay Nicolas, Meier Bernhard, Kohler Hans P
Laboratory for Thrombosis Research, Department of Clinical Research, Inselspital, University Hospital of Bern, Bern, Switzerland.
Thromb Haemost. 2002 Dec;88(6):1020-5.
Due to its role in the balance between coagulation and fibrinolysis, thrombin activatable fibrinolysis inhibitor (TAFI) may be involved in the development of cardiovascular diseases. We studied 362 patients with coronary artery disease (CAD) and 134 control subjects free of CAD, both groups investigated by angiography. TAFI antigen levels were determined in venous and intracoronary plasma samples and were related to metabolic and hemostatic risk factors and extent of coronary atherosclerosis. Venous TAFI levels tended to be higher in CAD patients compared to controls, whereas this difference was significant in intracoronary samples. A subgroup of patients who had not experienced acute myocardial infarction or undergone previous cardiac interventions showed significantly higher TAFI levels in both venous and intracoronary plasma samples. TAFI levels correlated with acute phase reactants indicating a role for TAFI in inflammation. However, TAFI levels did not correlate with extent of coronary atherosclerosis and among the classical cardiovascular risk factors TAFI levels only correlated with total cholesterol and fibrinogen concentration. Our results suggest that TAFI might be a risk factor for the development of CAD.
由于凝血酶激活的纤溶抑制物（TAFI）在凝血与纤溶平衡中发挥作用，它可能参与心血管疾病的发生发展。我们研究了362例冠心病（CAD）患者和134例无CAD的对照者，两组均通过血管造影进行检查。测定了静脉血和冠状动脉内血浆样本中的TAFI抗原水平，并将其与代谢和止血危险因素以及冠状动脉粥样硬化程度相关联。与对照组相比，CAD患者的静脉TAFI水平往往更高，而在冠状动脉内样本中这种差异具有显著性。未经历过急性心肌梗死或未接受过心脏介入治疗的患者亚组，其静脉血和冠状动脉内血浆样本中的TAFI水平均显著更高。TAFI水平与急性期反应物相关，表明TAFI在炎症中发挥作用。然而，TAFI水平与冠状动脉粥样硬化程度无关，在经典心血管危险因素中，TAFI水平仅与总胆固醇和纤维蛋白原浓度相关。我们的结果提示，TAFI可能是CAD发生的一个危险因素。
